Adial Pharmaceuticals Competitors
| ADIL Stock | USD 2.00 0.13 6.95% |
Correlation: Adial Pharmaceuticals vs Biocardia Snapshot
Very weak diversification
For the present investment horizon, the measured correlation between ADIL and BCDA stands at 0.48, or Very weak diversification. This matters because lower overlap can improve diversification, while higher overlap leaves more of the same risk inside the portfolio.
Moving against Adial Stock
The mean reversion principle applied to Adial Pharmaceuticals' suggests that neither prolonged outperformance nor underperformance is permanent. Investors exploit this by positioning against extremes in price relative to fundamental value.
Adial Pharmaceuticals Competition Correlation Matrix
Studying peer correlation around Adial Pharmaceuticals gives investors a cleaner read on how much independent price behavior still exists across the competitive set. The useful question is whether competitors are behaving like true alternatives or simply tracking the same sector move with different volatility.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Adial Stock performing well and Adial Pharmaceuticals Company doing well as a business compared to the competition. Risk-adjusted metrics allow investors to compare Adial Pharmaceuticals' efficiency and downside exposure against peers in a more meaningful way. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NRSN | 3.95 | 0.05 | 0.00 | -0.05 | 0.00 | 8.51 | 28.83 | |||
| ACXP | 8.55 | 1.88 | 0.26 | 0.79 | 6.06 | 27.26 | 130.49 | |||
| MTNB | 4.31 | -0.03 | 0.00 | -0.93 | 0.00 | 8.96 | 32.48 | |||
| BCLI | 4.81 | 0.87 | 0.16 | 1.56 | 4.87 | 12.90 | 26.67 | |||
| APRE | 4.50 | 0.04 | 0.00 | -0.06 | 0.00 | 11.29 | 46.26 | |||
| HCWB | 6.18 | -0.56 | 0.00 | -0.32 | 0.00 | 15.46 | 99.25 | |||
| KPRX | 2.12 | 0.10 | 0.06 | 0.08 | 2.28 | 3.96 | 12.37 | |||
| CDIO | 9.24 | 0.99 | 0.07 | 0.15 | 9.94 | 25.48 | 117.59 | |||
| CELZ | 3.32 | 0.08 | 0.00 | -0.06 | 0.00 | 7.17 | 25.03 | |||
| BCDA | 2.44 | -0.04 | 0.00 | -0.19 | 0.00 | 5.98 | 20.06 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Adial Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Adial Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Compare Adial Pharmaceuticals and related stocks such as Neurosense Therapeutics, Acurx Pharmaceuticals LLC, and Matinas BioPharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRSN | -1.2 M | -1.2 M | -1.2 M | -1.2 M | -1.2 M | -1.2 M | -1.2 M | -1.2 M | -1.2 M | -1.2 M | -2.8 M | -4 M | -12.3 M | -10.1 M | -10.2 M | -9.2 M | -9.6 M |
| ACXP | -5.9 M | -5.9 M | -5.9 M | -5.9 M | -5.9 M | -5.9 M | -5.9 M | -5.9 M | -5.9 M | -5.9 M | -4.6 M | -12.7 M | -12.1 M | -14.6 M | -14.1 M | -8 M | -8.4 M |
| MTNB | -116.1 K | -116.1 K | -116.1 K | -3.7 M | -10.2 M | -9.1 M | -7.6 M | -15.5 M | -14.1 M | -17.4 M | -22.4 M | -23.3 M | -21 M | -22.9 M | -24.3 M | -21.8 M | -22.9 M |
| BCLI | -25.6 K | -3.9 M | -3.4 M | -4.9 M | -9.2 M | -8.5 M | -5 M | -5 M | -13.9 M | -23.3 M | -31.8 M | -24.5 M | -23.7 M | -17.2 M | 11.6 M | 10.5 M | 11 M |
| APRE | -3.5 M | -254 K | -254 K | -436.2 K | -15.2 M | -15.2 M | -15.2 M | -15.2 M | -15.5 M | -28.1 M | -53.9 M | -36.5 M | -112.7 M | -14.3 M | -13 M | -12.6 M | -13.2 M |
| HCWB | -7.3 M | -7.3 M | -7.3 M | -7.3 M | -7.3 M | -7.3 M | -7.3 M | -7.3 M | -7.3 M | -7.3 M | -5.8 M | -12.9 M | -14.9 M | -25 M | -30 M | -27 M | -25.7 M |
| KPRX | -6 M | -6 M | -6 M | -3.9 M | -1.8 M | -8.4 M | -13.3 M | -13.2 M | -10.8 M | -7.1 M | -6.9 M | -13.8 M | -13.6 M | -12.5 M | 3.6 M | 3.2 M | 3.4 M |
| CDIO | -605.2 K | -605.2 K | -605.2 K | -605.2 K | -605.2 K | -605.2 K | -605.2 K | -605.2 K | -605.2 K | -605.2 K | -605.2 K | -620.4 K | -4.7 M | -8.4 M | -8.4 M | -6.5 M | -6.8 M |
| CELZ | 1.4 K | -24.1 K | -25.6 K | -27.3 K | -28 K | -30.8 K | -766.1 K | -2.7 M | -13.7 M | -8.5 M | -36.3 M | 19.2 M | -10.1 M | -5.3 M | -5.5 M | -6 M | -5.7 M |
| BCDA | 135.6 K | 9.7 M | 305 K | 19 K | 234 K | 322 K | -10.3 M | -12.3 M | -14 M | -14.7 M | -15 M | -12.6 M | -11.9 M | -11.6 M | -7.9 M | -7.2 M | -6.8 M |
Adial Pharmaceuticals Competitive Analysis
How does Adial Pharmaceuticals measure up against Neurosense Therapeutics, Acurx Pharmaceuticals, and Matinas BioPharma? The financials tell a nuanced story. The company holds a 2.7 M market capitalization. Adial Pharmaceuticals posts a -170.73% return on equity, reflecting current earnings headwinds. Return on equity favors Adial Pharmaceuticals at -170.73%, well ahead of Neurosense Therapeutics at -2478.16%. On pure scale, Acurx Pharmaceuticals is the bigger entity with market caps of 16.9 M versus 2.7 M. Matinas BioPharma holds the larger valuation at 3.8 M versus 2.7 M.| Better Than Average | Worse Than Peers | View Performance Chart |
Adial Pharmaceuticals Competition Peer Performance Charts
How to Analyze Adial Pharmaceuticals Against Peers
Adial Pharmaceuticals' peer analysis compares Adial Pharmaceuticals with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Adial Pharmaceuticals trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Adial Pharmaceuticals leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Analyzing Adial Pharmaceuticals' peers expands diversification context, relative positioning, and sector theme understanding. Valuation premiums or discounts for Adial Pharmaceuticals become more meaningful when measured against the peer group rather than in isolation. Relative analysis can highlight whether current pricing already reflects peer-group strengths or weaknesses. For peer comparison, Adial Pharmaceuticals has a market cap of 2.67 M.
Inputs for Adial Pharmaceuticals come from periodic company reporting and market reference feeds and are mapped into a consistent schema for analysis. Some fields can appear with publication lag.